Lv45
600 积分 2023-10-23 加入
The dual role of DNA repair protein MGMT in cancer prevention and treatment
18天前
已完结
Analyzing the scaffold diversity of cyclin‐dependent kinase inhibitors and revisiting the clinical and preclinical pipeline
21天前
已完结
Protein degraders push into novel target space
27天前
已完结
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy
28天前
已完结
Emerging strategies to investigate the biology of early cancer
29天前
已完结
The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment
30天前
已完结
Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES)
1个月前
已完结
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
1个月前
已完结
Complex synthetic lethality in cancer
1个月前
已完结
NAFLD and NASH: etiology, targets and emerging therapies
2个月前
已完结
皖公网安备34019202002308
